Overview

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Status:
Not yet recruiting
Trial end date:
2029-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants may or may not have already had treatment for their cancer. Participation could last up to six years.
Phase:
Phase 3
Details
Lead Sponsor:
Loxo Oncology, Inc.